Home›Trial›NCT06208878
NCT06208878ENROLLING BY INVITATION

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Study Summary

This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies

Conditions
Hematologic MalignancySolid Malignancy
Interventions / Drugs
Non Interventional
View on ClinicalTrials.gov ↗
Sponsor
CRSP
CRISPR Therapeutics
Gene Editing
D47/100
Study Details
Enrollment70 participants
Primary Completion—
Lead SponsorCRISPR Therapeutics AG
Data Retrieved2026-04-11 04:10:52.768024+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 70 participants
Sponsor Catalyst Profile

CRISPR Therapeutics (CRSP) is the sponsoring company for this trial. BiotechSign currently grades this company D (47/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

CRSP Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.